Driehaus Capital Management 13F: Cuts GH Stake by $95M

Driehaus Capital Management lowered its stake in Guardant Health, Inc. (NASDAQ: GH) by 28.9% during the period ended May 15, 2026, according to its latest Form 13F filing with the Securities and Exchange Commission. The fund disposed of 618,911 shares, bringing its remaining holdings to 1,524,282 shares. The position was valued at $234,343,123.05 at the close of the reporting period.

Driehaus Capital Trims Guardant Health Holdings

Before the reduction, the investment firm held 2,143,193 shares of the precision oncology company. By selling off 618,911 shares, Driehaus Capital Management reduced its total exposure but still maintains a substantial position worth over $234.3 million. Because 13F filings are submitted after the close of each quarter, these figures represent the fund's portfolio as of mid-May 2026 and may not reflect its current holdings today.

Guardant Health Stock Price and Market Metrics

Shares of Guardant Health traded at $153.74 on Saturday, placing the stock above its 200-day moving average of $120.63 but below its 50-day moving average of $161.34. The company has experienced wide price swings over the past year, trading between a 52-week low of $55.38 and a 52-week high of $183.51. With a market capitalization of $23,332,687,422.65, the company does not have a meaningful P/E ratio because it is currently not profitable.

Recent Earnings and Financial Growth

Guardant Health reported annual revenue of $1,183,105,024.00, representing a revenue growth rate of 44.3%. The company posted an earnings per share loss of $3.52 and a net margin of negative 38.3%. The company has a current ratio of 4.03, showing strong short-term liquidity. Investors are looking forward to the company's next scheduled earnings report on October 28, 2026.

Guardant Health Insider Transactions

Recent updates show mixed activity among company insiders. On June 26, 2026, Co-Chief Executive Officer Amirali Talasaz acquired 111,804 shares at $4.18 per share, totaling $467,340.72. On that same day, he also filed a transaction involving another 111,804 shares at a price of $0.00. Later in the year, on October 14, 2026, Director Alex M. Azar II sold 69 shares through a planned transaction under a Rule 10b5-1 trading plan. The sale was executed at $159.89 per share, valued at $11,032.41.

Wall Street Analyst Views on Guardant Health

Analysts have shown strong support for the stock, with 26 opinions yielding a consensus recommendation of strong_buy and a mean price target of $196.38. Several firms adjusted their outlooks recently. On October 13, 2026, Morgan Stanley maintained an Overweight rating and lifted its target to $200.00 from $185.00. On October 7, 2026, Barclays maintained its Overweight rating and raised its target to $220.00 from $200.00. Guggenheim maintained a Buy rating with a $200.00 target on October 1, 2026. Earlier, on September 9, 2026, UBS kept a Buy rating and increased its target to $225.00, while Rothschild & Co initiated coverage with a Buy rating and a $203.00 price target on September 8, 2026. BTIG reiterated a Buy rating on September 2, 2026, maintaining a $195.00 target. In August, both Piper Sandler and Stephens & Co. maintained Overweight ratings, with targets of $193.00 and $195.00, respectively.

Precision Cancer Testing and Biotechnology

Guardant Health is a precision oncology company that develops advanced blood and tissue tests to detect and monitor cancer. Its products include liquid biopsy tests like Guardant360 and Shield, which help doctors analyze tumor genetics and screen for colorectal cancer without invasive procedures. The company's focus on non-invasive cancer screening has made it a closely watched player in the medical diagnostics space.

What to Watch at Guardant Health, Inc.

Market observers will likely keep a close eye on the company's upcoming earnings report on October 28, 2026, to see if revenue growth continues to outpace its losses. While institutional adjustments like the one by Driehaus Capital Management provide a window into professional investor sentiment, these reports only reflect a past snapshot of holdings. Future regulatory filings will reveal whether other major funds have followed suit or expanded their stakes.